



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>G01N 33/558, 33/58, 33/68</b>	<b>A1</b>	(11) International Publication Number: <b>WO 97/37222</b> (43) International Publication Date: 9 October 1997 (09.10.97)
---	-----------	---

(21) International Application Number: PCT/US97/04754

(22) International Filing Date: 27 March 1997 (27.03.97)

(30) Priority Data:  
08/625,048 29 March 1996 (29.03.96) US

(60) Parent Application or Grant

(63) Related by Continuation

US 08/625,048 (CIP)  
Filed on 29 March 1996 (29.03.96)(71) Applicants (for all designated States except US): UNIVER-  
SITY OF BRITISH COLUMBIA [CA/CA]; IRC 331-2194,  
Health Sciences Mall, Vancouver, British Columbia VT6  
123 (CA). HAMILTON, BROOK, SMITH & REYNOLDS,  
P.C. [US/US]; Two Militia Drive, Lexington, MA 02173  
(US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): BROOKS, Donald, El-  
liott [CA/CA]; 3989 W. 19th Avenue, Vancouver, British  
Columbia (CA). DEVINE, Dana [CA/CA]; 3989 W. 19th  
Avenue, Vancouver, British Columbia (CA).(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith &  
Reynolds, P.C., Two Militia Drive, Lexington, MA 02173  
(US).(81) Designated States: CA, JP, US, European patent (AT, BE, CH,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
SE).**Published***With international search report.**Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: QUANTITATIVE IMMUNOCHROMATOGRAPHIC ASSAYS

## (57) Abstract

Quantitative im-  
munochromatographic assays  
for measuring the amount of  
an analyte, and an apparatus  
for use in the assays, are  
disclosed. The assays involve  
obtaining a fluid sample which  
contains the analyte; supplying  
a RAMP<sup>TM</sup> apparatus which  
includes a membrane having an  
application point, a detection  
zone, and a contact region,  
where the contact region is  
between the application point  
and the detection zone, and  
has antibody-coated particles  
imbedded within it; contacting  
the application point with the  
fluid sample; maintaining the  
RAMP<sup>TM</sup> apparatus under  
conditions sufficient to allow  
fluid to transport analyte by  
capillary action to the contact  
region, where the analyte  
binds to the antibody-coated  
particles; further maintaining

the apparatus under conditions sufficient to allow fluid to transport analyte-bound antibody-coated particles to the detection zone, where they interact with a detection reagent; and detecting the amount of analyte-bound antibody-coated particles which have reacted with the detection reagent. Alternatively, the fluid sample can be contacted with the detection zone of the apparatus, and the antibody-coated particles are mobilized by addition of fluid to the application point. The RAMP<sup>TM</sup> apparatus can additionally include one or more of the following features: a wicking pad; an application pad covering the application point; a contact pad covering the contact region; a separator pad between the membrane and the contact pad; and an internal control.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## QUANTITATIVE IMMUNOCHROMATOGRAPHIC ASSAYS

## BACKGROUND OF THE INVENTION

Quantitative analysis of cells and analytes in fluid samples, particularly bodily fluid samples, often provides critical diagnostic and treatment information for physicians and patients. For example, in a wide variety of clinical and therapeutic situations, blood platelet counts are routinely assessed; abnormalities in platelet counts can cause significant bleeding problems in a patient, and may indicate a multitude of underlying conditions. The early diagnosis of myocardial infarction is aided by quantification of myoglobin in a blood sample, as myoglobin is the earliest marker of cardiac damage (Mair, J. et al., *Br. Heart J.* 68:462-468 (1992)). Renal function and degree of kidney damage can be assessed by analyzing urine for the presence of proteinuria via urinary albumin measurement. Immunological testing methods (Kennedy, D.M. and S.J. Challacombe, eds., *ELISA and Other Solid Phase Immunoassays: Theoretical and Practical Aspects*, John Wiley and Sons, Chichester (1988)), which take advantage of the high specificity of the antigen-antibody reaction, provide one approach to measurement of analytes. Immunoassays which provide a quantitative measurement of the amount of an analyte in a sample use complex, multi-step procedures and expensive analyzers available only in a laboratory setting. Immunochemical assays, such as those described in GB 2,204,398A; U.S. patents 5,096,837, 5,238,652, and 5,266,497; Birnbaum, S. et al., *Analytical Biochem.* 206:168-171 (1992); Roberts, M.A. and R.A. Durst, *Analytical Chem.* 67:482-491 (1995); and Klimov, A.D. et al., *Clinical Chem.* 41:1360 (1995), are simpler, yet do not provide a quantitative measurement of an analyte. Instead, these immunochemical assays detect the presence (or

-2-

absence) of an analyte above a defined cutoff level for the test performed. Thus, there is a need for a general method that can provide a rapid, quantitative measurement of the amount of an analyte present in a sample, and that is  
5 sufficiently simple to carry out without use of a laboratory or an individual trained in chemical analysis.

#### SUMMARY OF THE INVENTION

The invention relates to methods of measuring the amount of an analyte of interest in a fluid sample, using a  
10 quantitative immunochromatographic assay; and an apparatus for use in the assay. The assay utilizes a rapid antigen measurement platform (RAMP™) apparatus. The apparatus includes a membrane strip made of a suitable material, such as cellulose nitrate or glass fiber, which has sufficient  
15 porosity and the ability to be wet by the fluid containing the analyte, and which allows movement of particles by capillary action. The membrane strip has an application point, a contact region, and a detection zone; the contact region is between the application point and the detection  
20 zone. Imbedded in the contact region is a population of particles, such as colloidal metal particles, organic molecules, liposomes, or organic polymer latex particles. The particles are coated with an antibody to the analyte of interest. The particles can be labelled, using a  
25 colorimetric, fluorescent, luminescent, or other appropriate label, to facilitate detection. A detection reagent is immobilized in the detection zone. The detection reagent can be antibody to the analyte of interest, or can be the analyte of interest itself. The  
30 apparatus can also include one or more of the following features: an application pad, which rests on and covers the application point; a contact pad, which rests on and covers the contact region, and which may have antibody-coated particles imbedded within it; if a contact pad is

-3-

present, a separator pad, which rests on the membrane in between the contact region and the contact pad; a wicking pad, which rests on the membrane adjacent to the detection zone, such that the detection zone is between the wicking  
5 pad and the contact region; and an internal control, which includes internal control particles imbedded in the contact region, a control detection reagent, and a control reaction zone.

To conduct the assay, the application point of the  
10 membrane strip is contacted with the fluid sample to be assayed for the analyte of interest. The apparatus is then maintained under conditions which are sufficient to allow capillary action of fluid to transport the analyte of interest, if analyte is present in the sample, through the  
15 membrane strip to the contact region. The apparatus is further maintained under appropriate conditions so that when analyte of interest reaches the contact region, the analyte binds to the antibody-coated particles imbedded in the contact region. Antibody-coated particles, including  
20 those which are bound with analyte, are mobilized by fluid and move by capillary action through the strip to the detection zone. The detection reagent interacts with analyte-bound antibody-coated particles; interaction of the detection reagent and the analyte-bound antibody-coated  
25 particles results in arrest of analyte-bound antibody-coated particles in the detection zone. The amount of analyte-bound antibody-coated particles that are arrested in the detection zone is then detected. The amount of analyte of interest in the fluid sample is related to the  
30 amount of analyte-bound antibody-coated particles that are arrested in the detection zone: if the detection reagent is the analyte of interest, the amount of analyte in the fluid sample is inversely related; if the detection reagent is antibody to the analyte of interest, the amount of  
35 analyte in the fluid sample is directly related. The

-4-

amount of analyte is determined from a standard curve for the analyte of interest.

In an alternative immunochromatographic assay, the fluid sample to be assayed for the analyte of interest is applied directly to the detection zone of the apparatus. In this embodiment, the detection reagent is antibody to the analyte of interest. The apparatus is maintained under appropriate conditions so that analyte in the fluid sample interacts with the detection reagent, and is immobilized in the detection zone. Water or an appropriate buffer is then added to the application point of the membrane, to mobilize the antibody-coated particles, which are moved by capillary action into the detection zone. The apparatus is further maintained under conditions which allow interaction of the antibody-coated particles with analyte that is immobilized in the detection zone. Interaction of the antibody-coated particles with immobilized analyte arrests movement of the antibody-coated particles. The amount of analyte in the fluid sample is related to the amount of antibody-coated particles that are arrested in the detection zone, and is determined from a standard curve, as described above.

In a preferred embodiment of the invention, the analyte of interest is thrombospondin, and the fluid sample is a whole blood sample or a platelet-rich plasma sample. Measurement of the thrombospondin concentration in clotted whole blood, or platelet-rich plasma sample, provides a measure of the platelet count in the original blood sample. This parameter is a critical measure of the ability of an individual to maintain normal hemostasis and is followed in a wide variety of clinical settings, including in patients undergoing chemotherapy or patients with platelet destructive disorders or abnormalities of platelet production.

In another preferred embodiment, the analyte of interest is myoglobin, and the fluid sample is a whole

-5-

blood sample. The concentration of myoglobin and its time dependence is of diagnostic importance in the early assessment of cardiac damage in suspected myocardial infarction.

5        In yet another preferred embodiment, the analyte of interest is human serum albumin (also referred to herein as urinary albumin), and the fluid sample is a urine sample. The concentration of urinary albumin is a measure of proteinuria and kidney damage, so the degree of renal  
10        dysfunction and its time course can be assessed through the quantitative measurement of albumin levels in urine.

      The assays of the current invention are simple, rapid, and usually require addition of no reagents other than a fluid sample containing the analyte, or, in one embodiment,  
15        a sample containing the analyte and a buffer solution. The assays can be performed at the point of care of a patient, and do not require skilled technical labor to perform. Furthermore, the apparatus used in the assays is common to all analytes, thus facilitating use of the assays for a  
20        wide variety of analytes. Quantification of a wide variety of immunogenic analytes can be performed with the assays.

#### BRIEF DESCRIPTION OF THE FIGURES

      Figure 1 is a depiction of the Rapid Antigen Measurement Platform (RAMP™) apparatus.

25        Figure 2 is a graphic representation of the relationship between the amount of arrested particles in the detection zone and concentration of antibody on the antibody-coated particles. The thrombospondin coating concentration, 240 µg/ml; latex concentration, 0.5%.

30        Figure 3 is a graphic representation of the relationship between the amount of arrested particles in the detection zone and concentration of the detection reagent (thrombospondin). Latex antibody surface concentration,  $2 \times 10^{-7}$  g/cm<sup>2</sup>; latex concentration 2%.

-6-

Figure 4 is a graphic representation of the relationship between the amount of arrested particles in the detection zone and concentration of antibody-coated particles. Latex antibody surface concentration,  
5  $2 \times 10^{-7}$  g/cm<sup>2</sup>; 15  $\mu$ l of 240  $\mu$ g/ml thrombospondin on membrane.

Figure 5 is a graphic representation of the relationship between the amount of thrombospondin in a fluid sample and the amount of arrested particles in the  
10 detection zone. Coating thrombospondin concentration, 240  $\mu$ g/ml; latex concentration, 0.5%.

Figure 6 is a graphic representation of the relationship between the concentration of human serum albumin (HSA) in a fluid sample (at low concentrations of  
15 HSA) and the signal of arrested, labelled particles in the detection zone.

Figure 7 is a graphic representation of the relationship between the concentration of human serum albumin (HSA) in a fluid sample (at high concentrations of  
20 HSA) and the signal of arrested, labelled particles in the detection zone.

#### DETAILED DESCRIPTION OF THE INVENTION

The current invention pertains to methods of quantitatively measuring the amount of an analyte using  
25 immunochromatographic assays, apparatus useful in the methods, and kits including the apparatus. As described herein, Applicants have developed a sensitive immunochromatographic assay to measure the level of a soluble, immunogenic analyte in solution.

30 The term, "analyte," as used herein, refers to the molecule or compound for which the amount will be measured. Examples of analytes include proteins, such as hormones or enzymes; glycoproteins; peptides; small molecules; polysaccharides; antibodies; nucleic acids; drugs; toxins;



-7-

viruses or virus particles; portions of a cell wall; and other compounds. The analyte is "immunogenic," which indicates that antibodies (as described below) can be raised to the analyte. In preferred embodiments, the  
5 analyte is thrombospondin, myoglobin, or urinary albumin.

To conduct the immunochromatographic assays of the current invention, a rapid antigen measurement platform (RAMP™) apparatus is used. Figure 1 depicts the RAMP™ apparatus. The RAMP™ apparatus includes: a membrane  
10 strip (10) having an application point (12), a contact region (14), and a detection zone (16). The membrane strip can be made of a substance having the following characteristics: sufficient porosity to allow capillary action of fluid along its surface and through its interior;  
15 the ability to allow movement of antibody-coated particles by capillary action (i.e., it must not block the particles); and the ability to be wet by the fluid containing the analyte (e.g., hydrophilicity for aqueous fluids, hydrophobicity for organic solvents).  
20 Hydrophobicity of a membrane can be altered to render the membrane hydrophilic for use with aqueous fluid, by processes such as those described in U.S. Patent 4,340,482, or U.S. Patent 4,618,533, which describe transformation of a hydrophobic surface into a hydrophilic surface. Examples  
25 of membrane substances include: cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone. In a preferred embodiment, the membrane strip is made of cellulose  
30 nitrate.

The "application point" (12), as used herein, is the position on the membrane where the fluid sample is applied. The RAMP™ apparatus can optionally include an "application pad" (22) which rests on the membrane, covering the  
35 application point. The application pad can be made of an

-8-

absorbent substance which can deliver a fluid sample, when applied to the pad, to the application point on the membrane. Representative substances include cellulose or glass fibers.

5       The "contact region" of the membrane is adjacent to the application point. The RAMP™ apparatus can optionally include an "contact pad" (24) which rests on the membrane, covering the contact region. The contact pad can be made of an absorbent substance; representative substances  
10 include cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone. If a contact pad is present, the RAMP™ apparatus can also optionally include a "separator pad" (26) which rests on  
15 the membrane, between the contact region and the contact pad. The separator pad can be made of an absorbent substance; representative substances include cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic  
20 copolymer/nylon, and polyethersulfone. In a preferred embodiment, if a separator pad and a contact pad are both present, they are made of the same substance.

Imbedded in the "contact region" of the membrane, and/or in the contact pad if it is present, is a population  
25 of particles which are coated with antibodies (or other types of molecules that specifically bind) to the analyte of interest. The population of particles varies, depending on the size and composition of the particles, the composition of the membrane, and the level of sensitivity  
30 of the assay. The population typically ranges approximately between  $4 \times 10^6$  and  $4 \times 10^9$  particles, although fewer than  $4 \times 10^6$  particles can be used. In a preferred embodiment, the population is approximately  $4 \times 10^8$  particles.

-9-

The particles imbedded in the contact region are particles which can be coated with antibodies or with other agents that specifically bind to the analyte. Examples of substances include colloidal gold particles; colloidal sulphur particles; colloidal selenium particles; colloidal barium sulfate particles; colloidal iron sulfate particles; metal iodate particles; silver halide particles; silica particles; colloidal metal (hydrous) oxide particles; colloidal metal sulfide particles; colloidal lead selenide particles; colloidal cadmium selenide particles; colloidal metal phosphate particles; colloidal metal ferrite particles; any of the above-mentioned colloidal particles coated with organic or inorganic layers; protein or peptide molecules; liposomes; or organic polymer latex particles.

15 In a preferred embodiment, the particles are polystyrene latex beads, and particularly, polystyrene latex beads that have been prepared in the absence of surfactant, such as surfactant-free Superactive Uniform Aldehyde/Sulfate Latexes (Interfacial Dynamics Corp., Portland, OR). The

20 size of the particles is related to porosity of the membrane: the particles must be sufficiently small to be transported along the membrane by capillary action of fluid.

The particles can be labelled to facilitate detection.

25 Examples of labels include luminescent labels; colorimetric labels, such as dyes; fluorescent labels; or chemical labels, such as electroactive agents (e.g., ferrocyanide).

The particles are coated with an agent that specifically binds to the analyte of interest. In a

30 preferred embodiment, the particles are coated with antibodies to the analyte of interest. The antibodies can be monoclonal antibodies or polyclonal antibodies. The term "antibody", as used herein, also refers to antibody fragments which are sufficient to bind to the analyte of

35 interest. Alternatively, molecules which specifically bind

-10-

to the analyte of interest, such as engineered proteins having analyte binding sites, can also be used (Holliger, P. and H.R. Hoogenbloom, *Trends in Biotechnology* 13:7-9 (1995); Chamow, S.M. and A. Ashkenazi, *Trends in Biotechnology* 14:52-60:1996)). In another embodiment, if the analyte of interest is a ligand, a receptor which binds to the ligand can be used. If the analyte is an antibody of known specificity, the particles can be coated with the antigen against which the analyte-antibody is directed.

10       The contact region of the membrane is between the application point and the "detection zone" (16) of the membrane. The detection zone, as described herein, refers to a point on the membrane strip at which a "detection reagent" is immobilized. In one embodiment, the detection reagent is the analyte of interest. In a second embodiment, the detection reagent is antibody directed against the same epitope of the analyte, or against a different epitope of the analyte, as those antibodies coated onto the particles.

20       The RAMP™ apparatus can also optionally include a "wicking pad" (28). The term, "wicking pad," as used herein, refers to an absorbent substance which soaks up solution that has been transported by capillary action to the end of the membrane strip. Examples of substances include cellulose and glass fiber.

25       In order to compensate for variations in membrane properties from assay to assay, the apparatus can additionally include an internal control, which includes internal control particles, a control detection reagent, and a control reaction zone (32). Internal control particles are imbedded in the contact region with the antibody-coated particles. The "internal control particles" are identical to the antibody-coated particles, and are coated with the same surface concentration of an antibody, except the antibody on the internal control

30       

35

-11-

particles is directed against a control detection reagent which does not react with the antibody directed against the analyte. The "control detection reagent" can be a reagent which does not interact with either the analyte to be  
5 measured, the antibody on the antibody-coated particles, or the detection reagent. In a preferred embodiment, the control detection reagent is Keyhole Limpet Hemocyanin (KLH). The control detection reagent is coated on the membrane in a "control reaction zone" (32). The control  
10 reaction zone, as described herein, refers to a point on the membrane strip at which the control detection reagent is immobilized. The control reaction zone can be between the contact region and the detection zone; alternatively, the detection zone can be between the contact region and  
15 the control reaction zone.

To perform the quantitative immunochromatographic assay, a fluid sample containing the analyte of interest is obtained. The fluid can be a fluid that wets the membrane material; that supports an antibody/antigen reaction (i.e.,  
20 does not interfere with antibody/antigen interaction); and that has a viscosity that is sufficiently low to allow movement of the fluid by capillary action. In a preferred embodiment, the fluid is an aqueous solution (such as a bodily fluid).

25 In a first embodiment of the quantitative assay, the application point of the membrane strip is contacted with the fluid sample containing the analyte of interest. If the apparatus includes an application pad, the fluid sample is applied to the application pad, which delivers the fluid  
30 sample to the application point. After the membrane strip is contacted with the fluid sample containing the analyte of interest at the application point, the membrane strip is maintained under conditions which allow fluid to transport the analyte by capillary action to the "contact region" of  
35 the membrane.

-12-

When the analyte is transported to the contact region, analyte that is present in the fluid binds to the antibody-coated particles imbedded in the contact region. If a contact pad, or a contact pad and a separator pad, are present, the pads facilitate controlled release of antibody-coated particles, and contact with a larger volume of the fluid sample with the antibody-coated particles. "Binding" of analyte to the antibody-coated particle indicates that one or more of the antibodies coated onto the particle are bound to analyte of interest. An antibody-coated particle which is "insufficiently bound" is one at which the binding sites of the antibodies coated onto the particle are not completely filled by the analyte of interest, such that antibody on the particle is capable of binding to additional analyte. An antibody-coated particle which is insufficiently bound to analyte of interest, as described herein, can be bound to some analyte, or to no analyte. If no further analyte can be bound to the antibody-coated particle, the antibody-coated particle is said to be "saturated" with analyte.

Antibody-coated particles which have been maintained under conditions allowing analyte in the fluid to bind to the antibody-coated particles imbedded in the contact region, and/or the contact pad, if present, are referred to herein as "contacted antibody-coated particles". Contacted antibody-coated particles may or may not have analyte bound to the antibodies, depending on whether or not analyte is present in the fluid sample and whether analyte has bound to the antibody on the antibody-coated particles.

Capillary action of the fluid from the fluid sample mobilizes the contacted antibody-coated particles, and moves the contacted antibody-coated particles along the membrane to a "detection zone" on the membrane. The movement of contacted antibody-coated particles is arrested by binding to the detection reagent. If the detection

-13-

reagent is the analyte of interest, the detection reagent binds to antibody on those contacted antibody-coated particles which are insufficiently bound to analyte of interest. If the detection reagent is antibody to the analyte of interest, the detection reagent binds to analyte which is bound to antibody on the contacted antibody-coated particles. The term, "detection-reagent-particle complexes", as used herein, refers to a complex of the detection reagent and contacted antibody-coated particles.

10 The detection-reagent-particle complexes are arrested (e.g., immobilized) in the detection zone.

The amount of detection-reagent-particle complexes arrested in the detection zone is detected. If the antibody-coated particles have been labelled, the complexes are detected using an appropriate means for the type of label. Alternatively, the amount of detection-reagent-particle complexes is detected by an optical method, such as by measuring the light scattering in the detection zone. The amount of detection-reagent-particle complexes can also be measured using electrical conductivity or dielectric (capacitance). Alternatively, electrochemical detection of released electroactive agents, such as indium, bismuth, gallium or tellurium ions, as described by Hayes et al. (*Analytical Chem.* 66:1860-1865 (1994)) or ferrocyanide as suggested by Roberts and Durst (*Analytical Chem.* 67:482-491 (1995)), can be used. For example, if liposomes are used, ferrocyanide encapsulated within the liposome can be released by addition of a drop of detergent at the detection zone, and the released ferrocyanide detected electrochemically, as outlined by Roberts and Durst. If chelating agent-protein conjugates are used to chelate metal ions, addition of a drop of acid at the detection zone will release the ions and allow their quantitation by anodic stripping voltametry as described by Hayes et al.

-14-

The amount of analyte in the fluid sample is then determined, based on the amount of detection-reagent-particle complexes arrested in the detection zone. If the detection reagent is the analyte of interest, the amount of  
5 analyte of interest in the fluid sample is inversely related to the amount of detection-reagent-particle complexes arrested in the detection zone. If the detection reagent is the antibody, the amount of analyte of interest in the fluid sample is directly related to the amount of  
10 arrested detection-reagent-particle complexes in the detection zone.

The amount of analyte of interest can be determined through the use of a standard curve. The standard curve is generated by preparing a series of control samples,  
15 containing known concentrations of the analyte of interest in the fluid in which the analyte is to be detected (such as serum depleted of the analyte). The quantitative immunochromatographic assay is then performed on the series of control samples; the amount of detection-reagent-  
20 particle complexes in the detection zone is measured for each control sample; and the amounts are plotted as a function of the concentration of analyte included in the control sample. Samples containing an unknown amount of analyte (the "test samples") are assayed by measuring the  
25 amount of detection-reagent-particle complexes for the test sample, and the concentration of analyte in the test sample is determined by referring to the standard curve. One standard curve can be generated and used for all test samples; it is not necessary that the standard curve be re-  
30 generated for each test sample. The standard curve is recalibrated for each different detection reagent.

If internal control particles are used in the assay, the internal control particles are mobilized by fluid, and are moved by capillary action to the control reaction zone.  
35 The internal control particles bind to the control



-15-

detection reagent in the control reaction zone, generating internal control particle-control detection reagent complexes (herein referred to as "control complexes"). The amount of control complexes is detected in the same manner as the amount of detection-reagent-particle complexes in the detection zone. The ratio (R) of the amount of detection-reagent-particle complexes to the amount of control complexes present, is used to determine the amount of analyte present, utilizing a standard curve. The standard curve is generated by preparing a series of control samples, containing known concentrations of the analyte of interest in the fluid in which the analyte is to be detected (such as serum depleted of the analyte). The quantitative immunochromatographic assay is then performed on the series of control samples; the value of R is measured for each control sample; and the R values are plotted as a function of the concentration of analyte included in the control sample. Samples containing an unknown amount of analyte (the "test samples") are assayed by measuring the value of R for the test sample, and the concentration of analyte in the test sample is determined by referring to the standard curve. As above, one standard curve can be generated and used for all test samples; it is not necessary that the standard curve be re-generated for each test sample.

In a second embodiment of the invention, the detection zone of the membrane strip, rather than the application point, is contacted with the fluid sample. In this embodiment, the detection reagent is antibody to the analyte of interest. The membrane strip is maintained under conditions which are sufficient to allow analyte of interest in the fluid sample to bind to the antibody in the detection zone, thereby generating immobilized analyte. Subsequently, the application point of the membrane is contacted with water or a buffer. The buffer can be an

-16-

aqueous fluid that wets the membrane material; that supports an antibody/antigen reaction (i.e., does not interfere with antibody/antigen interaction); and that has a viscosity that is sufficiently low to allow movement of the fluid by capillary action. Examples of buffers include, for example, saline, or 50 mM Tris-HCl, pH 7.4. The buffer transports the population of antibody-coated particles imbedded in the membrane at the contact region and/or contact pad to the detection zone. The membrane strip is further maintained under conditions which are sufficient to allow the immobilized analyte to interact with the antibody-coated particles. Interaction of immobilized analyte with antibody-coated particles arrests the movement of the antibody-coated particles, and generates arrested analyte-particle complexes. The amount of arrested analyte-particle complexes in the detection zone is then measured, as described above, and the amount of analyte in the fluid sample is determined using a standard curve, as described above, and can be determined with or without an internal control. The amount of analyte of interest in the fluid sample is directly related to the amount of arrested analyte-particle complexes in the detection zone.

In a preferred embodiment of the invention, the analyte of interest is thrombospondin, and the fluid sample is a whole blood sample, or a platelet-rich plasma sample derived from whole blood. A platelet-rich plasma sample is isolated from the blood sample, using standard methods. In order to conduct the quantitative assay for thrombospondin using whole blood or a platelet-rich plasma sample, thrombospondin must be released from the platelets, either before application of the sample to the apparatus, or by application of the sample to the apparatus. Thrombospondin can be released from platelets in the whole blood sample or in the platelet-rich plasma sample by methods such as a

-17-

releasing agent or contact activation. Releasing agents such as thrombin, calcium ionophore A23187, phorbol esters and detergents, can all be used to release thrombospondin from platelets. Alternatively, thrombin generation by the  
5 natural clotting process that is initiated by contact activation when blood is drawn into glass containers in the absence of anticoagulant is sufficient for release of thrombospondin. In a preferred embodiment, the RAMP™ apparatus includes an application pad, which is used to  
10 release thrombospondin from platelets. The whole blood sample, or the platelet-rich plasma sample is applied to the application pad, and release of the thrombospondin results. The application pad can additionally be impregnated with one or more releasing agent(s), such as  
15 those described above, to facilitate release of thrombospondin. The thrombospondin released by the releasing agent or by contact activation is referred to herein as "released thrombospondin." The detection reagent can be thrombospondin, an antibody to thrombospondin, or  
20 another suitable agent. The standard curve for thrombospondin can be generated by preparing a series of control samples of known concentrations of thrombospondin in serum containing no detectable thrombospondin. The quantitative immunochromatographic assay is performed on  
25 the series of control samples; the amount of detection-reagent-particles complexes in the detection zone is determined for each control sample; and the values are plotted as a function of the concentration of thrombospondin included in the control samples.

30 The amount of thrombospondin in a sample can be used to determine the platelet count of an individual, based on a relationship between the amount of thrombospondin released from platelets in a sample and the platelet count. A reference curve for the relationship between platelet  
35 count and thrombospondin in standard samples can be

-18-

generated, and the platelet count determined from the amount of thrombospondin in the test samples.

Alternatively, a reference curve can be generated by plotting the amount of thrombospondin as a function of platelet concentration in a series of control samples of blood containing a known number of platelets. More detailed teachings concerning the relationship between thrombospondin and platelet count are described in U.S. Patent Application Serial Number 08/625,770 (Attorney Docket Number UBC95-095), entitled "Determination of Platelet Count Employing Assay for Platelet Granule Proteins", filed on March 29, 1996, the entire teachings of which are incorporated herein by reference.

In another preferred embodiment of the invention, the analyte of interest is myoglobin. The sample can be, for example, whole blood, such as anticoagulated whole blood; plasma; or serum. In a preferred embodiment the sample is whole blood. The apparatus preferentially includes an application pad and an internal control (comprising internal control particles, a control detection reagent, and a control reaction zone). Preferentially, a monoclonal antibody directed against myoglobin is used as the detection reagent, and is coated on the membrane in the detection zone. The membrane is blocked with a suitable agent, such as 1% PVA. The quantitative immunochromatographic assay is initiated by adding the fluid sample to the application pad, and the assay is allowed to proceed. The ratio (R) of the amount of detection reagent-particle complex in the detection zone to the amount of control complexes in the control reaction zone is used to determine the amount of myoglobin present, using a standard curve. The standard curve is generated by preparing a series of control samples of known concentrations of myoglobin in whole blood, plasma or serum, containing no detectable myoglobin. The

-19-

quantitative immunochromatographic assay is performed on the series of control samples; the value of R is calculated for each control sample; and the R values are plotted as a function of the concentration of myoglobin included in the  
5 control sample.

The analyte of interest is urinary albumin in another preferred embodiment, and the fluid sample is a urine sample. Albumin is used as the detection reagent, and is coated on the membrane in the detection region. The  
10 membrane is blocked as described above. The assay is initiated by applying a urine sample to the application pad, and the assay allowed to proceed. The standard curve is generated by performing the quantitative immunochromatographic assay on a series of control samples  
15 of urine free of detectable albumin, to which are added known amounts of albumin.

The invention also includes kits which contain the apparatus described herein. Other kit components can include: buffers, fluid collection means, and control  
20 samples for generation of a standard curve.

The invention is further illustrated by the following examples, which are not intended to be limiting in any way.

Example 1 Quantitative Immunochromatographic Assay for  
Thrombospondin

25 Experiments were conducted to facilitate membrane selection and selection of blocking agents; and to examine conditions for latex release and migration, conditions for latex migration arrest, and the dependence of inhibition of latex migration arrest on free analyte concentration.

-20-

### A. Membrane Selection

A suitable membrane was selected by determining the binding characteristics of the detection reagent to the membrane and the rate of capillary flow through the  
5 membrane. The important binding characteristics are the affinity and capacity of the membrane for the detection reagent and the lack of reversibility of binding by buffer, blocking reagents or proteins (such as plasma proteins) present in the fluid sample to be analyzed that might  
10 compete for binding sites on the membrane.

#### 1. Equilibrium Binding of Thrombospondin to Membranes

Experiments were conducted to determine the amount of thrombospondin adsorbed to various membranes under  
15 equilibrium conditions, and to determine the amount of thrombospondin (fraction) desorbed from membrane surfaces by competition with serum proteins. The membranes used are shown in Table 1.

-21-

**TABLE 1** Membranes used in Thrombospondin Equilibrium Binding Studies

Supplier	Membrane Material	Pore Size ( $\mu$ )	Thickness (cm)	Average Dry Weight (used in expts.) (g)	Geometric "Surface" Area* ( $\text{cm}^2/\text{g}$ )
Sartorius					
NC5	Nitrocellulose	5	0.014	0.00215	279.68
NC8	Nitrocellulose	8	0.014	0.0021	286.34
Gelman					
NT5000	Nitrocellulose	5	0.0139	0.00195	308.37
NF10	Nitrocellulose	10		0.0015	400.88
A/E	Glass Fibre	1	0.0456	0.00423	142.16
MSI					
M5	Nylon	5	0.1	0.00325	185.02
M10	Nylon	10	0.1	0.00273	220.26
S&S					
NC5	Nitrocellulose	5	0.0139	0.0023	261.44
NC8	Nitrocellulose	8	0.0126	0.0022	273.33

\*The geometric "surface" area quoted is simply the area of the circular membrane disc, the thickness of the membrane disc was not taken into consideration.

$^{125}\text{I}$ -thrombospondin was prepared by iodinating 100  $\mu\text{g}$  of thrombospondin with 10  $\mu\text{l}$  of  $\text{Na}^{125}\text{I}$  (0.1 mCi) using Iodobeads (Pierce Chemicals, Rockford, IL). Unconjugated  $^{125}\text{I}$  was removed by gel filtration (Sephadex G-25) and  
5 diluted with unlabelled thrombospondin to give a stock 20 ml of approximately 200  $\mu\text{g}$  thrombospondin/ml (specific activity approximately 463 CPM/ $\mu\text{g}$  thrombospondin) in Tris-HCl buffer (50 mM, pH 7.4).

Circular membrane discs (0.875 cm in diameter) were  
10 obtained by punching holes through the membranes using an

-22-

arch punch. The average dry weight of each membrane disc was determined by weight in 3 or 4 membrane discs.

Dry membrane discs were soaked in 1 ml solutions containing (i) 20, (ii) 40, (iii) 80, and (iv) 200  $\mu\text{g/ml}$  thrombospondin, made from the stock solution above, and allowed to equilibrate overnight without shaking. The membranes were then transferred to new tubes, and the radioactivity of the membrane and original thrombospondin solution were measured to obtain the equilibrium thrombospondin concentration and the amount of thrombospondin bound on the membranes. The thrombospondin binding capacity of each membranes was determined by Scatchard plots (Cantor, C.R. and P.R. Schimmel, Biophysical Chemistry, Part III. The Behavior of Biological Macromolecules, W.H. Freeman Co., San Francisco (1980), p. 856). A summary of the thrombospondin binding capacity of the membranes is shown in Table 2.



**Table 2** Summary of Thrombospondin Binding Capacity of Membranes

Membrane		Saturation binding values of thrombospondin ( $\mu\text{g/g}$ ) to membranes	Saturation binding values of thrombospondin ( $\mu\text{g/cm}^2$ )* to membranes
Sartorius			
	NC5	2586.5	9.25
	NC8	1954.7	6.83
Gelman			
	NT5000	3712.2	12.04
	NF10	503.0	1.25
	A/E	6686.5	47.03
MSI			
	M5	1388.1	7.50
	M10	1370.4	6.22
S&S			
	NC5	1662.0	6.36
	NC8	1236.0	4.52

\*The geometric "surface" area used in estimating the saturation binding values of thrombospondin in ( $\mu\text{g/cm}^2$ ) is simply the area of the circular membrane disc, the thickness of the membrane disc was not taken into consideration.

The maximum surface concentration of thrombospondin ( $\mu\text{g/g}$ ) shows that the thrombospondin binding capacity of the membranes increase in the order:

A/E > NT5000 > NC5 > NC8 > S&S NC5 > M5 > M10 > S&S NC8  
5 > NF10.

Generally, membranes with small effective pore size (1 and 5  $\mu\text{m}$ ) bind more thrombospondin per unit weight than those with large effective pore size (8 and 10  $\mu\text{m}$ ), except for the NC8 membrane, which appears to bind more

-24-

thrombospondin than the smaller effective pore size S&S N5 and M5 membranes. This is presumably because there is more fibre material available for adsorption, per unit weight, in the small effective pore size membranes than in the large effective pore size membranes. There is considerable variation in the binding capacity of membranes with similar material, effective pore size, and thickness, as exhibited by the (Sartorius) NC5, (Gelman) NT5000, and the (S&S) NC5.

The reversibility of adsorption was then studied.

Membranes were washed with Tris-HCl buffer (50 mM, pH 7.4) by static soaking for 15 minutes and the amount of thrombospondin retained on the membranes was determined by gamma counting. The membranes were subjected to three cycles of wash procedure, counting the radioactivity each time to determine the amount of thrombospondin retained. After the third buffer wash, membranes were incubated in 1 ml of serum for 15 minutes and the amount of thrombospondin retained determined by gamma counting. Exposing the membranes carrying adsorbed thrombospondin to buffer washes two or three times effectively removed unbound thrombospondin within the membrane interstices. Membranes washed in buffer after having thrombospondin adsorbed overnight, did not desorb significantly, when exposed to potentially competing serum proteins (data not shown).

## 2. Thrombospondin Binding to Membrane by Spot-Wetting

To apply the detection reagent to the detection zone, a solution of detection reagent is sprayed or applied in drops to the detection zone of the membrane (spot wetting). In this process the detection reagent dries onto the membrane surfaces to which it has access, from a solution whose concentration will change as the medium evaporates or

-25-

migrates by capillarity through the fibers, a process that differs from that which occurs when a large volume of a solution of detection reagent is equilibrated with membrane. In latex immunochromatographic assays, the detection reagent is applied by wetting the target area; the membrane is then blocked with a polymer or detergent. Application of the blocking agent can displace bound detection reagent. Similarly, during the migration phase of the assay, as the wetting front advances up the membrane and reaches the target area, blocking agents can be swept along with the wetting front and displace detection reagent. Therefore, experiments were conducted to determine thrombospondin binding characteristics on membranes under conditions similar to those under which immunochromatographic assays are performed, and to determine membrane capacity to retain bound thrombospondin at the point of application following drying and rehydration by various blocking agents.

Because of its binding properties, the Sartorius NC5 membrane was selected for further study. Membrane (Sartorius NC5) was cut into strips (1.5 cm by 9.0 cm) and divided into six square sections (1.5 cm by 1.5 cm). The size of square was chosen such that a 10  $\mu$ l solution of thrombospondin would spread on the membrane to just fill the square.

To examine reversal of thrombospondin by blocking agents, 10  $\mu$ l of radiolabelled thrombospondin was spot blotted on the second square section, near one end of the membrane strip and allowed to dry overnight. The membrane strips were then dipped in 1% w/v blocking agent in Tris-HCl buffer (50 mM, pH 7.4) such that the section with bound thrombospondin was just above the blocking solution, and the blocking solution was allowed to wick to the other end of the membrane. The membrane strips were then dried overnight and cut into sections (1.5 cm by 1.5 cm) and each

section counted to determine the amount of thrombospondin retained and/or displaced along the membrane strip by the blocking agent. Results are shown in Table 3.

**Table 3** Amount of Thrombospondin on Membrane Sections as Percent of Total Amount Immobilized

Blocking agent	Amount of thrombospondin left on membrane sections after incubation in blocking agent solutions								
	NC5	NC8	NT5000	NF10	A/E	M5	M10	S&S5	S&S8
PVA (15,000)	72	76	72	64	72	86	97	61	57
PVA (22,000)	89	86	74	63	75	94	82	80	71
PVA (49,000)	68	70	77	48	76	52	65	75	68
PVP (40,000)	87	82	80	64	61	74	99	83	78
PEG (6,000)	92	75	72	67	63	78	86	85	77
PEG (20,000)	88	86	61	82	71	79	88	97	71
Dextran T500	98	83	94	71	90	86	93	83	78
Pluronic P-105	74	68	67	63	71	79	85	61	51
Triton X-100	53	70	68	56	67	73	64	49	75
Tween 20	45	65	75	51	67	71	69	40	73
BSA	73	79	86	77	62	82	85	67	76
Buffer (Tris-HCl)	88	85	83	77	55	82	83	86	82

In general, most of the water soluble polymers did not displace thrombospondin that has been immobilized and air dried on (NC5) membrane to a great extent. With the exception of PVA (15,000), all the water soluble polymers used as blocking agents displaced thrombospondin, under wicking conditions, to the same extent as Tris-HCl buffer and BSA. Based on the adsorption results, the amount of thrombospondin released by buffer should largely represent the amount of thrombospondin dried into the membrane but not directly associated with membrane fibers. All the neutral detergents (Tween 20 and Triton X-100) and a

surfactant copolymer (Pluronic P-105) used as blocking agents displaced thrombospondin, under wicking conditions, to a greater degree than the water soluble polymers, BSA, and Tris-HCl buffer. Nevertheless, even these agents left  
5 at least 60% of the applied thrombospondin on target.

To determine how much thrombospondin was removed by blocking agents drying onto membrane and being rehydrated, the membrane strip section, with the thrombospondin spot, was soaked in Tris-HCl buffer for approximately 15 minutes  
10 after the blocking agents had wicked up the membrane in the above experiments, and the radioactivity of the strip section and the buffer solution used for re-equilibration were re-counted. Results are shown in Table 4.

Table 4. Thrombospondin on (Sartorius) NC5 Membrane Strip As a Percent of Amount on Membrane Strip Section With Thrombospondin Spot

Blocking agent	% thrombospondin
PVA (15,000)	93
PVA (22,000)	94
PVA (49,000)	90
PVP (40,000)	92
PEG (6,000)	96
PEG (20,000)	95
Dextran T500	95
Pluronic P-105	94
Triton X-100	94
Tween 20	93
BSA	97
Buffer (Tris-HCl)	96

-28-

Subsequent washing in buffer released little further thrombospondin, indicating that dried-on blocking agents, when wetted, did not significantly displace thrombospondin already associated with the membrane.

5           3.     Rate of Capillary Flow of Buffer and Serum  
              Through Membranes

Experiments were conducted to determine the migration rate of buffer and serum along a specified length of membrane. Membranes enumerated in Table 1 were cut into  
10 strips (1.0 cm by 6.0 cm) and divided into six sections (1.0 cm by 1.0 cm). Each membrane strip was placed vertically in a tube with the bottom of each strip immersed in buffer (Tris-HCl, 50 mM, pH 7.4) or fresh human serum. After allowing the fluid front to migrate 2 cm, the time  
15 required for the fluid migration through each subsequent cm was recorded. Results are shown in Table 5.

**Table 5**    Summary of Buffer and Serum Migration Rates in Membranes

Membrane		Time for buffer to migrate 4 cm along membrane (minutes)	Time for serum to migrate 4 cm along membrane (minutes)
Sartorius			
	NC5	3.97	5.17
	NC8	3.17	3.27
Gelman			
	NT5000	5.47	9.20
	NF10	3.40	3.87
	A/E	1.60	3.27
MSI			
	M5	5.40	11.50
	M10	2.53	3.70
S&S			
	NC5	3.53	7.33
	NC8	3.87	2.98

Except for the NT5000 membrane, Tris buffer (50mM, pH 7.4) showed similar flow rate (3-4 minutes/4 cm) for all the nitrocellulose membranes (NC5, NC8, NF10, S&S NC5, and S&S NC8) with no clear difference in the flow rate with respect to effective pore sizes, except for the NT5000 which was significantly slower. The effect of effective pore size was more pronounced in the flow rate of serum: membranes with larger effective pore sizes (8-10  $\mu$ m) showed similar flow rate as in buffer, while membranes with smaller effective pore sizes (1-5  $\mu$ m) showed a much reduced flow rate in serum than in buffer. Sartorius NC5 provided

-30-

the fastest serum flow for the smaller effective pore size membranes.

### B. Selection of Membrane Blocking Agents

Methods for "blocking" the membrane so that antibody-coated latex would not adhere to the membrane in the presence of serum proteins were investigated.

#### 1. Equilibrium Binding of IgG to Membranes

Experiments were conducted to determine the amount of IgG adsorbed to various membranes under equilibrium conditions, and to determine the amount of IgG retained on surfaces after wash cycle with buffer and blocking agent. Dry membrane discs (diameter = 0.875 cm) were soaked in 2 ml solutions containing (a) 5, (b) 10, (c) 25, (d) 50, (e) 100, and (f) 200  $\mu\text{g/ml}$  of radiolabelled IgG, and allowed to equilibrate overnight, at room temperature, without shaking. The membranes were then transferred to new tubes and the radioactivity of the membranes and IgG solution measured to obtain the equilibrium IgG concentration, and the amount bound on the membranes. Membranes were then washed in tris-HCl buffer (50 mM, pH 7.4) by static soaking for 15 minutes and the amount of IgG retained on the membranes was determined by gamma counting. The membranes were then subjected to another cycle of buffer wash, and 1% PVA (average molecular weight = 15,000) solution in tris-HCl buffer (50 mM, pH 7.4).



-31-

Re-equilibrating the membranes bearing adsorbed IgG in fresh buffer two times appeared to remove most of the unbound IgG within the membrane interstices. The solution of 1% PVA (15,000) displaced a considerable amount of IgG bound to the nitrocellulose membranes, whereas for the glass fibre and nylon membranes, it did not appear to remove as much bound IgG (data not shown), suggesting that PVA (15,000) would probably be a better blocking agent for the nitrocellulose membranes than for the glass fibre and the nylon membranes.

## 2. IgG Binding to Membranes by Spot-Wetting

Experiments were conducted to determine IgG binding characteristics under conditions similar to those under which immunochromatographic assays are performed, and to determine the amount of IgG retained on membranes after incubating in blocking agent solution and serum.

Dry membranes were cut in square sections (1.5 cm by 1.5 cm) and 10  $\mu$ l of radiolabelled IgG was spot blotted on each membrane section and allowed to air-dry for 3 hours. The amount of IgG immobilized on the membrane strips was determined by gamma counting. Air-dried membrane sections were first incubated in (2 ml) solution of 1% PVA (15,000) in tris-HCl buffer for 15 minutes then transferred to new tubes and counted again in gamma-counter to determine the amount of IgG retained. Membranes were then incubated in 2 ml serum for 15 minutes (X 2), transferred to new tubes and counted in gamma-counter after each wash incubation in serum.

The results indicated that a considerable amount of IgG bound onto nitrocellulose membranes by spot blotting was displaced by incubation of the membranes in 1% PVA solution, whereas only a relatively small amount of IgG was displaced from the glass fibre and nylon membranes.

-32-

Subsequent incubation of the membranes with serum did not displace IgG already blocked by 1% PVA.

### 3. IgG Binding to Blocked Membranes

Experiments were conducted to determine the effectiveness of various blocking agents on the membranes, and to determine whether the buffer wash cycle has any effect on the blocking agents.

Circular membrane discs (diameter = 0.875 cm) were obtained by punching holes through the membranes with an arch punch. The dry membrane discs were soaked in 1 ml solutions of various blocking agents and allowed to equilibrate overnight. The membrane discs were then transferred to new tubes and air-dried for approximately 3 hours before incubating in 1 ml solution containing 200  $\mu$ g/ml of radiolabelled IgG. Membranes were then washed in Tris-HCl buffer (50 mM, pH 7.4) and counted for gamma-radiation to determine amount of IgG bound. The buffer wash was repeated and the membranes counted again for gamma-radiation. After the second buffer wash, the membranes were re-equilibrated with 1 ml solution containing 200 mg/ml of radiolabelled IgG for 15 minutes. A further buffer wash was done to determine the amount of IgG retained on the membranes.

Results indicated that the amount of IgG bound to blocked membranes was considerably less than the amount bound to membranes that were not blocked, i.e. membranes equilibrated with IgG in Tris-HCl buffer. Except for the glass fibre and nylon membranes, PVA (15,000), PVA (22,000), PVA (49,000) & PVP (40,000) effectively blocked the binding of IgG to all the nitrocellulose membranes (data not shown). The other water soluble polymers, PEG (6,000), PEG (20,000) and Dextran, were not as good blocking agents as PVA and PVP were for all the membranes, except in the case of the glass fibre membrane-A/E (data

-33-

not shown). Among the neutral detergents (Tween 20, Pluronic P-105, and Triton X-100), Tween 20 appeared to block the nitrocellulose and nylon membranes better than Triton and Pluronic. Furthermore, Triton and Pluronic did not block the glass fibre (A/E) and Nylon membranes (M5 & M10) effectively. BSA generally blocked all the membranes fairly well; however, it was not as effective in blocking the nitrocellulose membranes as PVA and PVP. Re-equilibrating the membranes in IgG indicated that the wash cycles with buffer did not have any effect on the blocking agents used prior to binding IgG (data not shown).

#### 4. Binding of IgG in Serum to Blocked Membranes

Experiments were conducted to determine the amount of IgG bound in the presence of serum to membranes blocked with various blocking agents.

Circular membrane discs (diameter = 0.875 cm) were obtained by punching holes through the membranes with an arch punch. The dry membrane discs were soaked in 1 ml solutions of various blocking agents and allowed to equilibrate overnight. The membrane discs were then transferred to new tubes and air-dried for approximately 3 hours before incubating in 1 ml serum containing 200  $\mu$ g/ml of radiolabelled IgG. The amount of IgG bound to membranes were determined by gamma-count before and after buffer wash. The results indicated that, in the presence of serum, IgG binding to membranes that were pre-blocked with various blocking agent was negligible. Serum acted as a blocking agent as well since the membranes that were not blocked, i.e. those incubated in tris-HCl buffer with serum and radiolabelled IgG, did not bind any appreciable amount of IgG (data not shown).

-34-

### C. Conditions for Latex Release and Migration

In assays described herein, coated particles are dried into the contact zone of the membrane (and/or the contact pad). Experiments indicated that application of particles  
5 either by spraying a suspension with an air brush, or by adding small drops manually, was acceptable.

To examine the conditions for latex release and migration, a 30% sucrose solution in water was applied to an area of membrane and allowed to dry. Latex (0.5% in 15%  
10 buffered sucrose) was then added to the same area and dried; the membrane was then dipped in buffer or serum, and migration was allowed to proceed. Although the initial sucrose layer aided re-hydration, it obstructed the migration of latex particles through the membrane strip,  
15 especially when serum was used as the release agent.

The most straightforward method of application for experimental purposes was manual addition of the latex suspension with a micropipette. From 0.25 to 2% latex in buffered 15% sucrose is applied directly to the blocked  
20 membrane and allowed to dry briefly before migration is initiated.

An Aero-Pro 150 airbrush (Hansa-Technik GmbH, Hamburg, Germany) was assessed as an applicator for latex. Use of the air brush gave an even distribution of latex though the  
25 membrane; however, there was no way to quantify the amount of latex suspension applied with the manual apparatus. This approach will work if a metered amount and rate is available for the pressurized air spray. Such a method of distribution is appropriate for large scale applications.

-35-

#### D. Conditions for Latex Migration Arrest

In assays described herein, coated particles migrate by capillary action to the detection region, where they react with detection reagent and are immobilized as

5 detection-reagent-particle complexes, and are subsequently detected.

The conditions for latex migration arrest were investigated. A Sartorius NC8, mylar backed membrane was used. A 10  $\mu$ l solution of thrombospondin in buffer was  
10 dried at the detection zone and the membrane was blocked with 1% PVA (15,000) overnight. Blue 0.29  $\mu$ m sulphate/aldehyde latex particles (IDC) were coated with different concentrations of antibody and blocked with 1% BSA. Different concentrations of particles, suspended in  
15 buffered 15% sucrose, were applied to the contact region. Migration was induced by applying buffer containing various concentrations of thrombospondin to the application point of the membrane. Arrested latex at the detection zone was quantitated by image analysis of magnified video images of  
20 the detection zone. The signal used was the total difference in grey levels between the detection zone and the surrounding membrane area.

The results of these experiments demonstrated that the signal increases approximately linearly with latex antibody  
25 surface concentration (Figure 2), thrombospondin membrane coating concentration (Figure 3), and latex particle concentration (Figure 4).

Thus, the higher the antibody surface concentration, the greater the number of latex particles arrested in the  
30 target region. Furthermore, the number of particles arrested increased strongly with latex concentration, showing only a slight tendency to saturation up to 2% latex. The number of particles arrested increased with increasing thrombospondin concentration in the solution  
35 dried into the target area of the membrane, up to about 25

-36-

$\mu\text{g/ml}$  thrombospondin. Above this amount, the amount of latex arrested increased little when the thrombospondin concentration increased (e.g., a ten fold increase shown produced only a small increment over the 25  $\mu\text{g/ml}$  value).

- 5 It was therefore clear that the number of particles arrested in the target zone can be controlled independently by varying the latex number, the surface concentration of antibody on the latex and the thrombospondin concentration dried into the target area.

10        E. Dependence of Inhibition of Latex Migration  
          Arrest on Free Antigen Concentration

- In these experiments, latex migration took place by including various concentrations of free thrombospondin in the migration buffer into which one end of the membrane is  
15 dipped to produce latex movement. The free thrombospondin inhibits arrest in the target area by competing with antibody binding sites on the latex. The results, shown in Figure 5, demonstrated that the signal detected in the detection zone was continuously decreased as the  
20 concentration of the free antigen in the fluid sample was increased. These results thus demonstrated, both visually and quantitatively, the inhibition of particle arrest by free thrombospondin in a concentration dependent manner.

25        Example 2 Quantitative Immunochromatographic Assay for  
          Human Serum Albumin

- Experiments were conducted to measure the concentration of human serum albumin (HSA) at very low concentrations, to demonstrate that measurements made by quantitative immunoassays are comparable to those made with  
30 more complex and expensive immunoassays, such as enzyme-linked immunoassays (ELISAs). Experiments were performed using either low HSA concentrations, such as those expected in normal individuals, or high HSA concentrations that are

-37-

typical of those in samples from individuals suffering from renal damage.

#### A. Low HSA Concentration Assay

A polyclonal antibody preparation against HSA was used  
5 as the detection reagent, and the particles were coated  
with a monoclonal antibody directed against HSA. The  
monoclonal anti-HSA antibody was characterized by a  
dissociation constant,  $K_d$ , of 0.012  $\mu\text{g/ml}$ , indicating that  
an equilibrium concentration of 0.012  $\mu\text{g/ml}$  would fill half  
10 the antigen binding sites in the antibody population to  
which the test solution containing HSA was exposed.

##### 1. Preparation of the Latex Bead Particles

One ml of 0.98 mg/ml antibody, 1.0 ml of skim milk  
powder (Carnation) and 0.5 g of 2.0% w/v latex beads, all  
15 in 0.01 M phosphate buffer, pH 7.2, to a total volume of  
4.0 ml, were allowed to equilibrate. The beads were washed  
three times in the phosphate buffer, and then suspended to  
a 0.25% concentration in 15% sucrose, 0.5% Tween 20.

##### 2. Preparation of the Membrane

20 Ten  $\mu\text{l}$  of 0.44 mg/ml polyclonal anti-HSA antibody  
(Sigma Chemical Co., St. Louis, MO) was applied as  
detection reagent in the detection zone, 4 cm from a  
reference end of a 7 cm x 1 cm strip of 8  $\mu\text{m}$  pore size  
nitrocellulose membrane (Sartorius) and allowed to dry.  
25 The membrane was blocked with 1% w/v PVA 15,000 (Fluka).  
Five  $\mu\text{l}$  of the latex bead suspension was applied 1 cm from  
the reference end of the strip and allowed to dry.

##### 3. Assay for HSA

Solutions of HSA were prepared, with HSA  
30 concentrations from 0.0001  $\mu\text{g/ml}$  to 0.4  $\mu\text{g/ml}$  in 50 mM Tris  
buffer, pH 7.3. The solution was applied (120  $\mu\text{l}$ ) to the

-38-

reference end of the membrane and the solution was allowed to migrate by capillary action to the opposite end of the membrane. The membranes were then dried and the amount of latex beads accumulated in the detection zone was  
5 determined by optical image analysis. The results are shown in Figure 6, with the signal (corresponding to the amount of latex beads accumulated in the detection zone) plotted as a function of the HSA concentration. The results indicate that the assay detects HSA at  
10 concentrations below 0.01  $\mu\text{g/ml}$  (i.e., below the  $K_d$  value for the monoclonal antibody used). These results are comparable to results that can be obtained using clinical ELISA assays, which typically can detect concentrations of analyte equal to or greater than the value of  $K_d$  for the  
15 antibody used in the assay.

A similar assay was performed using samples of normal human urine instead of the HSA solutions. The levels of HSA present, as determined by the assay, were in agreement with the levels determined by an automated analyzer in a  
20 central clinical chemistry facility: the immunochromatographic assay gave values of 3.1  $\mu\text{g/ml}$  and 3.4  $\mu\text{g/ml}$ , compared to the automated analyzer values of 3.1  $\mu\text{g/ml}$  and 4.1  $\mu\text{g/ml}$ , respectively.

#### B. High HSA Concentration Assay

25 An inhibition assay was performed using pure HSA (Sigma Chemical Co.) as the detection reagent, to allow measurement of concentrations of HSA much greater than the  $K_d$  of the monoclonal antibody.

##### 1. Preparation of Latex Bead Particles

30 Aldehyde latex beads, 0.16  $\mu\text{m}$  in diameter and labeled with a yellow-green fluorescent dye (Interfacial Dynamics Corporation), were used. The beads were prepared as



-39-

described above, except the monoclonal antibody concentration was 1.75 mg/ml, and no skim milk was used.

## 2. Preparation of the Membrane

Membranes were prepared using 1 mg/ml HSA as the  
5 detection reagent. The HSA was sprayed on the detection zone at 2  $\mu$ l/cm with a Biodot applicator (BioDot, Inc., Irvine, CA), and allowed to dry.

## 3. Assay for HSA

Solutions of HSA were prepared, with HSA  
10 concentrations from 2  $\mu$ g/ml to 250  $\mu$ g/ml in 50 mM Tris buffer, pH 7.3. The solution was applied (200  $\mu$ l) to a cellulose contact pad on the reference end of the membrane and the solution was allowed to migrate by capillary action to the opposite end of the membrane. The membranes were  
15 then dried and the amount of latex beads accumulated in the detection zone was determined by fluorescence intensity measurement. The results are shown in Figure 7, with the signal (corresponding to the amount of latex beads accumulated in the detection zone) plotted as a function of  
20 the HSA concentration. The results indicate that increasing concentrations of HSA inhibited arrest of the latex beads in the detection zone. These results indicate that the assay is sensitive over the expected range (approximately 10-100  $\mu$ g/ml) of HSA in urine samples.

## 25 Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are  
30 intended to be encompassed in the scope of the following claims.

-40-

CLAIMS

What is claimed is:

1. A method for measuring the amount of an analyte of interest in a fluid sample, comprising quantitatively  
5 measuring the amount of analyte of interest in the sample using an immunochromatographic assay.
2. The method of Claim 1, wherein the immunochromatographic assay comprises the steps of:
  - 10 a. supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane strip, the membrane strip comprising an application point, a contact region, and a detection zone, wherein the contact region is between the application point and the detection  
15 zone;
  - b. contacting the application point of the membrane strip with the fluid sample;
  - c. maintaining the membrane strip under conditions which are sufficient to allow fluid to transport  
20 analyte of interest in the fluid sample by capillary action through the strip to the contact region, the contact region having a population of antibody-coated particles imbedded therein, wherein the antibody is an antibody to the  
25 analyte of interest;
  - d. further maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the antibody-coated particles, thereby generating contacted antibody-  
30 coated particles; to allow the fluid in the sample to transport the contacted antibody-coated particles by capillary action through the strip to the detection zone, the detection zone having

-41-

- a detection reagent immobilized thereon; and to allow the detection reagent to interact with contacted antibody-coated particles, thereby generating arrested detection-reagent-particle complexes; and
- 5 e. detecting the amount of arrested detection-reagent-particle complexes in the detection zone, wherein the amount of analyte of interest in the fluid sample is related to the amount of arrested detection-
- 10 reagent-particle complexes in the detection zone.
3. The method of Claim 2, wherein the detection reagent is the analyte of interest.
4. The method of Claim 2, wherein the detection reagent is an antibody to the analyte of interest.
- 15 5. The method of Claim 4, wherein the detection reagent is the antibody directed against the same or a different epitope as the antibody that is present on the antibody-coated particles.
6. The method of Claim 2, wherein the membrane strip is
- 20 made of cellulose nitrate or glass fiber.
7. The method of Claim 2, wherein the particles are latex beads.
8. The method of Claim 2, wherein the particles are labelled.
- 25 9. The method of Claim 8, wherein the label is selected from the group consisting of: colorimetric, fluorescent, and luminescent.

-42-

10. The method of Claim 2, wherein the analyte of interest is thrombospondin, and the fluid sample is blood or a platelet-rich plasma sample.
- 5 11. The method of Claim 10, wherein the detection reagent is thrombospondin.
12. The method of Claim 10, wherein the detection reagent is an antibody to thrombospondin.
- 10 13. The method of Claim 2, wherein the analyte of interest is myoglobin, and the fluid sample is selected from the group consisting of: whole blood, plasma, and serum.
14. The method of Claim 2, wherein the analyte of interest is urinary albumin, and the fluid sample is urine.
- 15 15. The method of Claim 1, wherein the immunochromatographic assay comprises the steps of:
  - 15 a. supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane strip, the membrane strip comprising an application point, a contact region, and a  
20 detection zone, wherein the contact region is between the application point and the detection zone;
  - 25 b. contacting the detection zone of the membrane strip with the fluid sample, the detection zone having an antibody to the analyte of interest immobilized thereon, and maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the antibody in the detection zone, thereby generating  
30 immobilized analyte;

-43-

- 5           c.     contacting the application point of the membrane with a buffer, and maintaining the membrane strip under conditions which are sufficient to allow buffer to transport a population of antibody-coated particles imbedded in the contact region, wherein the antibody is an antibody to the analyte, to the detection zone;
- 10           d.     further maintaining the membrane strip under conditions which are sufficient to allow immobilized analyte to interact with the antibody-coated particles, thereby generating immobilized analyte-particle complexes; and
- 15           e.     detecting the amount of immobilized analyte-particle complexes in the detection zone, wherein the amount of analyte of interest in the fluid sample is related to the amount of arrested detection-reagent-particle complexes in the detection zone.
- 20     16.    A method for quantitatively measuring the amount of an analyte of interest in a fluid sample to be assayed for the analyte of interest, comprising the steps of:
- 25           a.     supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane strip, the membrane strip comprising an application point, a contact region, and a detection zone, wherein the contact region is between the application point and the detection zone;
- 30           b.     contacting the application point of the membrane strip with the fluid sample;
- c.     maintaining the membrane strip under conditions which are sufficient to allow fluid to transport analyte of interest in the fluid sample by capillary action through the strip to the contact region, the contact region having a population of

-44-

antibody-coated particles imbedded therein,  
wherein the antibody is an antibody to the  
analyte of interest;

- 5           d.    further maintaining the membrane strip under  
              conditions which are sufficient to allow analyte  
              of interest to bind to the antibody-coated  
              particles, thereby generating contacted antibody-  
10           coated particles; to allow the fluid in the  
              sample to transport the contacted antibody-coated  
              particles by capillary action through the strip  
              to the detection zone, the detection zone having  
              the analyte of interest immobilized thereon; and  
              to allow the immobilized analyte of interest in  
15           the detection zone to bind to contacted antibody-  
              coated particles which are insufficiently coated  
              with the analyte of interest in the fluid sample;  
              and

- e.    detecting the amount of contacted antibody-coated  
20           particles bound to the immobilized analyte of  
              interest in the detection zone,

wherein the amount of analyte of interest in the fluid  
sample is inversely related to the amount of antibody-  
coated particles bound to the immobilized analyte of  
interest in the detection zone.

- 25   17.   A method for quantitatively measuring the amount of an  
          analyte of interest in a fluid sample to be assayed  
          for the analyte of interest, comprising the steps of:
- a.    supplying a rapid antigen measurement platform  
30           apparatus, the apparatus comprising a membrane  
              strip, the membrane strip comprising an  
              application point, a contact region, and a  
              detection zone, wherein the contact region is  
              between the application point and the detection  
              zone;

-45-

- b. contacting the application point of the membrane strip with the fluid sample;
- c. maintaining the membrane strip under conditions which are sufficient to allow fluid to transport analyte of interest in the fluid sample by capillary action through the strip to the contact region, the contact region having a population of antibody-coated particles imbedded therein, wherein the antibody is an antibody to the analyte of interest;
- d. further maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the antibody-coated particles, thereby generating contacted antibody-coated particles; to allow the fluid in the sample to transport the contacted antibody-coated particles by capillary action through the strip to the detection zone, the detection zone having an antibody directed against the same or a different epitope as the antibody on the particles immobilized thereon; and to allow the immobilized antibody in the detection zone to bind to analyte bound to the contacted antibody-coated particles; and
- e. detecting the amount of contacted antibody-coated particles bound to the immobilized antibody in the detection zone,
- wherein the amount of analyte of interest in the fluid sample is directly related to the amount of contacted antibody-coated particles bound to the immobilized antibody in the detection zone.
18. A method for quantitatively measuring the amount of an analyte of interest in a fluid sample to be assayed for the analyte of interest, comprising the steps of:

-46-

- a. supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane strip, the membrane strip comprising an application point, a contact region, a control reaction zone and a detection zone, wherein the contact region is between the application point and the detection zone;
- b. contacting the application point of the membrane strip with the fluid sample;
- c. maintaining the membrane strip under conditions which are sufficient to allow fluid to transport analyte of interest in the fluid sample by capillary action through the strip to the contact region, the contact region having a population of antibody-coated particles imbedded therein, wherein the antibody is an antibody to the analyte of interest, and a population of internal control particles imbedded therein, wherein the internal control particles are coated with an antibody to a control detection reagent;
- d. further maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the antibody-coated particles, thereby generating contacted antibody-coated particles; to allow the fluid in the sample to transport the contacted antibody-coated particles by capillary action through the strip to the detection zone, the detection zone having the analyte of interest immobilized thereon, and to allow the fluid in the sample to transport the internal control particles by capillary action through the strip to the control reaction zone, the control reaction zone having the control detection reagent immobilized thereon; to allow the immobilized analyte of interest in the



-47-

- detection zone to bind to contacted antibody-coated particles which are insufficiently coated with the analyte of interest in the fluid sample, and to allow the internal control particles to bind to the control detection reagent; and
- 5 e. detecting the amount of contacted antibody-coated particles bound to the immobilized analyte of interest in the detection zone, and the amount of internal control particles bound to the control
- 10 detection reagent,
- wherein the amount of analyte of interest in the fluid sample is inversely related to the amount of antibody-coated particles bound to the immobilized analyte of interest in the detection zone.
- 15 19. A method for quantitatively measuring the amount of an analyte of interest in a fluid sample to be assayed for the analyte of interest, comprising the steps of:
- a. supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane
- 20 strip, the membrane strip comprising an application point, a contact region, a control reaction zone and a detection zone, wherein the contact region is between the application point and the detection zone;
- 25 b. contacting the application point of the membrane strip with the fluid sample;
- c. maintaining the membrane strip under conditions which are sufficient to allow fluid to transport analyte of interest in the fluid sample by
- 30 capillary action through the strip to the contact region, the contact region having a population of antibody-coated particles imbedded therein, wherein the antibody is an antibody to the analyte of interest, and a population of internal

-48-

control particles imbedded therein, wherein the internal control particles are coated with an antibody to a control detection reagent;

- 5           d. further maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the antibody-coated particles, thereby generating contacted antibody-coated particles; to allow the fluid in the sample to transport the contacted antibody-coated particles by capillary action through the strip to the detection zone, the detection zone having an antibody directed against the same or a different epitope as the antibody on the particles immobilized thereon; and to allow the
- 10           immobilized antibody in the detection zone to bind to analyte bound to the contacted antibody-coated particles; to allow the immobilized antibody in the detection zone to bind to analyte bound to the contacted antibody-coated particles,
- 15           and to allow the internal control particles to bind to the control detection reagent; and
- 20           e. detecting the amount of contacted antibody-coated particles bound to the immobilized antibody in the detection zone, and the amount of internal control particles bound to the control detection reagent,
- 25

wherein the amount of analyte of interest in the fluid sample is directly related to the amount of contacted antibody-coated particles bound to the immobilized antibody in the detection zone.

30           

20. A method for measuring the amount of an analyte of interest in a fluid sample to be assayed for the analyte of interest, comprising the steps of:

-49-

- 5 a. supplying a rapid antigen measurement platform apparatus, the apparatus comprising a membrane strip, the membrane strip comprising an application point, a contact region, and a detection zone, wherein the contact region is between the application point and the detection zone;
- b. contacting the application point of the membrane strip with the fluid sample;
- 10 c. maintaining the membrane strip under conditions which are sufficient to allow fluid to transport analyte of interest in the fluid sample by capillary action through the strip to the contact region, the contact region having a population of particles imbedded therein, wherein the particles are coated with an agent that specifically binds to the analyte;
- 15 d. further maintaining the membrane strip under conditions which are sufficient to allow analyte of interest to bind to the coated particles, thereby generating contacted coated particles; to allow the fluid in the sample to transport the contacted coated particles by capillary action through the strip to the detection zone, the detection zone having a detection reagent immobilized thereon; and to allow the detection reagent to interact with contacted coated particles, thereby generating arrested detection-reagent-particle complexes; and
- 20 25 30 e. detecting the amount of arrested detection-reagent-particle complexes in the detection zone, wherein the amount of analyte of interest in the fluid sample is related to the amount of arrested detection-reagent-particle complexes in the detection zone.


-50-

21. A rapid antigen measurement platform apparatus for use in quantitative measurement of the amount of an analyte of interest in a fluid sample, said apparatus comprising:
- 5 a. a membrane strip having an application point, a contact region, and a detection zone, wherein the contact region is between the application point and the detection zone;
- 10 b. a population of antibody-coated particles imbedded in the contact region of the strip, wherein the antibody is an antibody to the analyte of interest; and
- c. a detection reagent immobilized in the detection zone of the strip.
- 15 22. The apparatus of Claim 21, wherein the detection reagent is the analyte of interest.
23. The apparatus of Claim 21, wherein the detection reagent is an antibody directed against the same or a different epitope as the antibody that is present on
- 20 the antibody-coated particles.
24. The apparatus of Claim 21, wherein the membrane strip is made of cellulose nitrate or glass fiber.
25. The apparatus of Claim 21, wherein the particles are latex beads.
- 25 26. The apparatus of Claim 21, wherein the particles are labelled.
27. The apparatus of Claim 26, wherein the label is selected from the group consisting of: luminescent, colorimetric, and fluorescent.


-51-

28. The apparatus of Claim 21, additionally comprising a wicking pad which rests on the membrane, wherein detection zone is between the contact region and the wicking pad.
- 5 29. The apparatus of Claim 21, additionally comprising an application pad, wherein the application pad rests on the membrane and covers the application point.
30. The apparatus of Claim 21, additionally comprising a contact pad, wherein the contact pad rests on the  
10 membrane and covers the contact region.
31. The apparatus of Claim 30, additionally comprising a separator pad, wherein the separator pad rests on the membrane between the membrane and the contact pad.
- 15 32. The apparatus of Claim 21, additionally comprising a population of internal control particles imbedded in the contact region, and a control detection zone on the membrane, the control detection zone having a control detection reagent immobilized thereon.


1/7

**FIGURE 1**

2/7


**FIGURE 2**

3/7


**FIGURE 3**




4/7

**FIGURE 4**

5/7

**FIGURE 5**

6/7

**FIGURE 7**

7/7




FIGURE 6

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 G01N33/558 G01N33/58 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 585 914 A (BECTON DICKINSON CO) 9 March 1994 see the whole document ---	1-17, 20-31
X	WO 92 22797 A (PACIFIC BIOTECH INC) 23 December 1992 see the whole document ---	1-17, 20-31
X	WO 94 29696 A (QUIDEL CORP) 22 December 1994 see the whole document ---	1-17, 20-31
A	EP 0 582 231 A (BECTON DICKINSON CO) 9 February 1994 see the whole document ---	18,19,32
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*A\* document member of the same patent family

Date of the actual completion of the international search

7 August 1997

Date of mailing of the international search report

26 -08- 1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Cartagena y Abella,P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/04754

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 34815 A (GKS TECHNOLOGIES ;GOMARD PHILIPPE (FR); KADOUCHE JEAN (FR); SAMAK) 21 December 1995 see the whole document ---	18,19,32
P,X	WO 97 09620 A (AGEN BIOMEDICAL LTD ;RYLATT DENNIS BRIAN (AU); MOSS DEAN (AU); JAN) 13 March 1997 see the whole document -----	1,18,19, 32

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 97/04754

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0585914 A	09-03-94	AU 659754 B	25-05-95
		AU 4476593 A	10-03-94
		CA 2105439 A	05-03-94
		JP 6174712 A	24-06-94
-----			
WO 9222797 A	23-12-92	AU 2247192 A	12-01-93
		CA 2110920 A	23-12-92
		EP 0588958 A	30-03-94
		JP 6508689 T	29-09-94
-----			
WO 9429696 A	22-12-94	EP 0705426 A	10-04-96
		JP 8511621 T	03-12-96
-----			
EP 0582231 A	09-02-94	AU 4427493 A	10-02-94
		CA 2101472 A	04-02-94
		DK 88293 A	04-02-94
		FI 933434 A	04-02-94
		JP 6167497 A	14-06-94
-----			
WO 9534815 A	21-12-95	FR 2721112 A	15-12-95
		CA 2197465 A	21-12-95
-----			
WO 9709620 A	13-03-97	AU 6782596 A	27-03-97
-----			